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Osteosarcoma remains a deadly malignancy aﬄicting adolescents and young adults. The lack of a precursor and the panoply of
genetic aberrations present in identiﬁed osteosarcomas makes study of its initiation diﬃcult. A number of candidate hypotheses
have been tested in the mouse, a species with a higher background incidence of osteosarcoma. Chemical carcinogens, external
beam radiation, and bone-seeking heavy metal radioisotopes have all proven to be osteosarcomagenic in wild-type mice. A
number of oncogenes, introduced via integrating viruses or aberrantly activated from heritable genetic loci, participate in and
can individually drive osteosarcomagenesis. Germline and conditional gene ablations in the form of some but not all aneuploidy-
inducing genes, conventional tumor suppressors, and factors that function normally in mesenchymal diﬀerentiation have also
proven osteosarcomagenic, especially in combinations that silence the Rb1 and p53 pathways. This paper reviews the rich history
of mouse models of osteosarcomagenesis, what they have taught us about the human disease, and what future mouse experiments
yet promise to teach.
1.Introduction
Osteosarcoma is the most common primary bone malig-
nancy and a leading cause of cancer death in adolescents and
young adults [1]. Phenotypically, osteosarcoma adheres to a
narrowly deﬁned pattern of disease.
Most osteosarcomas arise in the 2nd and 3rd decades
of life in the metaphyses of long bones, especially near the
major growth centers of the distal femur, proximal tibia,
and proximal humerus [1, 2]. When osteosarcoma rarely
develops in a patient over 40, it is usually secondary to
priorradiationexposureorPaget’smetabolicdiseaseofbone.
The vast majority of osteosarcomas (∼95 percent) present as
high-grade neoplasms, with microscopic metastatic disease
at presentation the expectation in every case [3]. Interme-
diate and low-grade variants of osteosarcoma are extremely
scarce [4]; benign bone-forming neoplasms are also much
more rare than conventional osteosarcoma itself. There is no
identiﬁable precursor to osteosarcoma.
Despite this narrow clinical phenotype, the genotype of
osteosarcoma aligns best with high-grade carcinomas, by
its many cytogenetic aberrations and multiple mutations.
It is diﬃcult to discern which of these many derangements
are causative of, as opposed to resultant from oncogenic
transformation. Naturally, when the ﬁnal state of these cells
fails to readily highlight the pathway of transformation that
engendered them, and no precursor lesion is known, scien-
tists turn to model systems to investigate cancer initiation
hypotheses.
Mouse models of human diseases have proven useful in
both mechanistic biological understanding of pathogenesis
and preclinical evaluation of medical interventions. For the
ﬁeld of cancer research, most mouse models have been
xenografts of human cells into immunocompromised mice.
Recent eﬀorts have extended to genetic mouse models of dis-
ease,giventheabilitytomanipulatethemurine genomewith
predictable facility. The modeling of osteosarcoma specif-
ically in mice predates the wide availability of xenografts
and even the technological innovations that permitted gene
targeting in the mouse.
Although much remains unknown regarding osteosarco-
magenesis, rodent models of osteosarcoma initiation have
taught us much and promise to have much more yet to
teach.2 Sarcoma
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Figure 1: Osteosarcomagenesis can be induced in genetically
wild-type mice through a variety of means. Most heavy metal
radioisotopes will naturally home to ossifying bone matrix in
the metabolically active metaphyses of long bones, emitting their
radiation locally after embedding. External beam radiation in
varied forms has also proven successfully osteosarcomagenic.
Although a few chemical carcinogens administered systemically by
oral or intravenous application in mice have proven suﬃcient, most
osteosarcomagenic chemical compounds have been orthotopically
implanted in the tibia or femur.
2. Random Mutagenesisand
Induced Chromosomal Instability
The background rate of osteosarcomagenesis in rodents is
higher than the background rate of most carcinomas and
much higher than the natural incidence of osteosarcoma in
humans, but is still low. Control mice in most induction
studies have under ﬁve percent natural lifetime incidence of
osteosarcoma. A mouse strain with a higher basal incidence
of osteosarcoma was reported in 1938 but may have carried
germline mutations in some important tumor suppressors
yet unrecognized [5].
2.1. Chemical Carcinogens. The ﬁrst report of chemically
induced murine osteosarcomagenesis was also in 1938. Drs.
Brunschwig and Bissell surgically placed crystals of 1,2-
benzpyrene mixed in cholesterol into the tibial medullary
cavitiesofafewmice.Oneoftheseformedaradiographically
andhistologicallyveriﬁedosteosarcoma8.5monthslater[6].
The same authors had previously produced nonosteogenic
sarcomas by the application of 3-methylcholanthrene [7].
Many reports of chemical carcinogen-induced osteosarco-
mas in mice and rats have followed, but a theme that began
with these ﬁrst two attempts has persisted: bulky-adduct-
forming heterocyclic compounds have generally proven
more eﬃcient in the induction of osteosarcomagenesis than
methylatingagents,whichtendtoproduceﬁbrosarcomas[8–
10].
The mechanisms by which these diﬀerent classes of
agents generate genetic instability are chromosomal insta-
bility from bulky-adduct-forming agents and microsatel-
lite instability derived from a mismatch repair defect in
methylating agents [11]. This observation says nothing
deﬁnitive about human osteosarcomagenesis but suggests
that chromosomal instability is an important element of the
genetic distress and instability involved in pathogenesis.
Most chemically induced mouse osteosarcomas have
arisen from orthotopically implanted chemical carcinogens
(Figure 1), arguing that environmental exposures to chem-
ical carcinogens may not play a large role in sporadic
human osteosarcoma incidence. One exception to this is the
oral administration of 1-(2-hydroxy-ethyl)-1-nitrosurea to
rats, which generated osteogenic or chondrogenic sarcomas
in 58 percent. Overall, chemical implant-related osteosar-
comagenesis has taught us primarily about the eﬀects of
varied methods of DNA damage, rather than necessarily
recapitulating the actual etiology of the human disease.
Althoughtworeportshaveconsideredanincreasedincidence
of osteosarcoma in pediatric and adult populations exposed
to pesticides, the links are yet to be veriﬁed in second
populations [12, 13].
2.2. Radiation. Since the observation of frequent osteosar-
comas arising among radium dial painters in 1931 [14],
there have been many attempts to induce osteosarcomas
by application of radiation to the rodent skeleton. Some of
this work in rabbits actually predated Brunschwig’s chemical
induction of a mouse osteosarcoma [15, 16]. Both external
beam and internal exposure to ﬁltered and unﬁltered rays
from radium, thorium, and roentgen radiation have proven
suﬃcient to induce osteosarcomas in rodents at high enough
doses [17–20]. Beyond ﬁtting the theme of DNA damage
readily inducing osteosarcoma, this has an obvious correlate
with human osteosarcomagenesis, as exposure to envi-
ronmental or therapeutically/diagnostically applied external
beam radiation is known to increase risk for osteosarcoma
[21]. Osteosarcoma is one of the more common radiation-
induced secondary cancers in humans.
Mice have otherwise been induced to initiate osteosarco-
magenesis with radioactive heavy metals [22–30]. These ions
tend naturally to home to the bone and incorporate in the
hydroxy-apatite crystals that mineralize the ossifying matrix,
each ion usually replacing a calcium ion in the structure.
Most of the successfully osteosarcomagenic radioisotopes
have been alpha emitters. One can certainly speculate as
to the particular variety of genomic damage caused by
alpha particles, but this observation may have had as much
to do with simple anatomical localization of the damage
to osteoprogenitors near the matrix mineralization front,
as alpha particles do not traverse multiple tissue planes
eﬃciently,duetotheirlargesize.Certainly,beta-emittersthat
home to bone have also proven osteosarcomagenic.
2.3. Viral Insertional Mutagenesis. Genomic distress can also
begeneratedbyinfectionwithintegratingretroviruses.Many
of the early mouse models of leukemia and lymphoma wereSarcoma 3
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Figure 2: Genetically wild-type cells can naturally accrue suﬃcient mutations to initiate osteosarcomagenesis in mice as evidenced by the
background incidence of osteosarcomas a little under 5 percent in most strains (A). Genetically induced aneuploidy alone, in most of its
forms, is ineﬃcient in osteosarcomagenesis (B). Expression of oncogenes as transgenes using native promoters, introduced via insertional
viral vectors or unmasked by radiation, can lead to benign and malignant bone neoplasia in mice (C). Inherited germline deletion of tumor
suppressors in heterozygosity or homozygosity or generation of mouse chimeras of cells with and without such deletions to avoid serious
developmental defects have proven the eﬃciency of many gene inactivations in osteosarcomagenesis (D). Another means by which severe
developmental phenotypes may be eschewed or potential cells of origin tested is by the use of conditional oncogene activation or conditional
tumor suppressor ablation, speciﬁed either temporally or, by tissue, spatially (E); combinations of tumor suppressor deletions, possible in
conditional ablation methods, have been very eﬃcient at driving osteosarcomagenesis.
driven by the mutations caused by integrating viral DNA
[31]. Cloning of these sites was the ﬁrst major source of
information regarding tumor suppressors and oncogenes in
general. There are no reports of osteosarcomas arising in
mice exposed to such insertional mutagenesis speciﬁcally,
but the contribution of such insertional mutations to
the osteosarcomagenesis induced by oncogene-expressing
integrating viruses has not fully been explored.
2.4. Gene Targeting. Bombarding the genome with a chem-
ical, radiation, or an integrating virus will necessarily have
pleiotropiceﬀects.Therehavebeenotherattemptstodistress
the genome in a more orderly fashion, by genetic manip-
ulation of mice (Figure 2). For instance, aneuploidy can be
readily induced via hypomorphic or ablated alleles of certain
cell cycle checkpoint and mitotic spindle assembly proteins.
Such aneuploidy induced from UbcH10 disruption [32],
Bub3 and/or Rae1 disruption [33], or RanBP2 disruption
[34] generates no statistically signiﬁcant increase in the
number of sarcomas arising. In contrast, homozygosity
for hypomorphic Bub1 does increase sarcoma incidence
to nearly 15 percent (from a 5-percent background) over
the 2-year lifespan typical of these mice [35]. The authors
did not identify how many, if any, of these sarcomas were
osteosarcomas. In another study the same group added
Bub1-induced aneuploidy to a background of heterozygosity
for a panel of tumor suppressors and identiﬁed induced
loss of heterozygosity of these tumor suppressors as one
mechanism of action for Bub1 oncogenesis [36].
Insertional mutagenesis can also be driven by trans-
posons in a controlled genetic fashion in murine somatic
cells. Similar to oncogenic mutations from insertional
retroviruses, most of the tumors that form in Sleeping
Beauty transposon mice, when it is activated throughout the
body, are leukemias and lymphomas [37]. Soft-tissue and
a few bone sarcomas have been generated but only with
cooperative mutations in p19Arf [38].4 Sarcoma
3. Oncogenes
The other mouse models of osteosarcoma that predated
the age of gene targeting were derived from insertional
viruses that expressed transforming oncogenes. FBJ murine
osteosarcoma virus and RFB osteoma viruses were identiﬁed
from spontaneous murine tumors and the FBR osteosar-
coma virus from noncellular extracts from a radiation-
induced murine osteosarcoma [39]. All of these viruses were
eventually noted to cause high expression of c-fos,w h i c h
became almost the deﬁnitional osteosarcoma oncogene [40,
41]. When transgenic mouse technology was possible in
the late 1980s, mice transgenic for high c-fos expression
similarly formed osteosarcomas consistently [42]. Then, c-
Jun, another powerful oncogene, was found to potentiate
c-fos-driven osteosarcomagenesis when coexpressed [43]. In
screening a number of spontaneous and radiation-induced
murine osteosarcomas, a variety of oncogenes were found
to be expressed, including c-abl,c - bas,c - fos,K - ras,a n dc -
myc.N op a r t i c u l a ro n c o g e n ea p p e a r e dt op r e d o m i n a t e[ 44].
So important were these oncogenes felt to be initially that a
theory became prominent in the literature during the 1980s
and 1990s that radiation-induced osteosarcomagenesis may
have as much to do with unsilencing of oncogenes as it does
with DNA and chromosomal damage [45, 46].
Perhaps involved with steps other than initiation, other
nonviral oncogenes have been found to have potential
importance in mouse osteosarcomagenesis. Comparative
genomic hybridization on osteosarcomas arising in p53
heterozygous mice identiﬁed a recurrent ampliﬁcation of
mouse chromosomal region 9A1 [47]. This corresponds to
an ampliﬁcation of chromosome 11 common in human
osteosarcomas. The antiapoptotic genes Birc1 and Birc2,a s
well as matrix metalloproteinase 13 were all found to be
upregulated by this ampliﬁcation. Knockdown of the expres-
sion of each impeded tumor growth following engraftments
into immunocompromised mice. Further, ezrin has been
highlighted as a major contributor to the metastatic pheno-
type in a particular in vivo-passaged murine osteosarcoma
cell line [48].
No discussion of oncogenes and their role would be
complete without mention of the Simian vacuolating virus
40 (SV40), a polyoma virus that readily causes osteosarcoma
in hamsters. Expression cassettes from the virus have proven
eﬀe c t i v ei np r o d u c i n go s t e o s a r c o m a si nm i c ea sw e l l[ 49–
52]. As the oncogenes produced function more as a means
of inactivating speciﬁc tumor suppressors, we will discuss
them in greater detail below, acknowledging that, while
SV40 T antigens function as tumor suppressors, they are
themselves overexpressed and pro-oncogenic, similar to
other oncogenes.
4. Tumor Suppressor Silencing
4.1. Retinoblastoma and p53 Pathways. The ﬁrst clues that
murine osteosarcomagenesis can be driven by Rb1 and
p53 pathway disruptions came in the high incidence of
osteosarcomas in mice with transgenic expression of the
SV40 large T antigen [49–52], which is known to bind and
silence members of the Rb1 and p53 cell cycle checkpoint
pathways, eﬀectively disrupting them. Conditional genetic
ablation of Rb1 and p53 speciﬁcally using the Cre-lox system
has also recently proven suﬃcient to drive short-latency
osteosarcomagenesis [53, 54]. Both research teams, who
published essentially identical mouse models based on this
technique, concluded that p53 silencing is necessary and
Rb1 silencing cooperative—but insuﬃcient alone—to drive
osteosarcomagenesis.
Germline heterozygosity for p53 ablation engenders a
variety of cancers, but approximately 25 percent of mice
heterozygous for p53 knockout will develop osteosarcomas
[55]. While the variety of tumors common in patients with
Li-Fraumeni syndrome is generally replicated in heterozy-
gous p53-deﬁcient mice, the relative rates of each are quite
diﬀerent. Lymphomas are much more common in murine
than in human Li Fraumeni, and carcinomas much less
common [56]. Homozygous knockout of p53 has a lower
incidence of osteosarcoma (4 percent), most likely due to the
high incidence of early mortality from lymphoma formation
[55]. Further studies have reverse-translated speciﬁc disease-
causing missense mutations from human cancer patients
into the mouse and have shown that some can behave
more like dominant negative than silent alleles. Heterozy-
gosity for a particular such missense mutation, replacing
the arginine at amino acid residue 172 with a histidine,
generated a 50% incidence of osteosarcoma with shorter
latency than typical for heterozygous p53 ablation [57].
Other experiments have conditionally ablated p53 alone in
osteoprogenitor cells. Homozygosity for this tissue-speciﬁc
p53 silencing eﬃciently produces osteosarcomas with near-
complete penetrance [58].
Germline homozygous deletion of Rb1 is not compatible
with life. Heterozygous Germline Rb1 disruption does not
generate osteosarcoma with any detectably increased inci-
dence,instarkcontrasttohumansheterozygousforgermline
RB ablation, who have a 500-fold increased incidence of
osteosarcoma [59]. Rb1 heterozygous mice also do not
develop retinoblastomas, whereas most humans with the
homologous genotype will have bilateral retinoblastomas
either congenitally or during infancy. This is possibly due
to the reduced stochastic likelihood of losing heterozygosity
in retinal cells given that they have undergone fewer cell
cycles prior to terminal diﬀerentiation in a mouse than in
a human. However, mouse chimeras bearing cells with Rb1
homozygous deletion also do not form retinoblastomas or
osteosarcomas. The explanation for this lack of tumorige-
nesis came in the discovery of a redundancy in the mouse
(but not in humans) among the pocket proteins, Rb1, p107,
and p130 [60]. It was ﬁrst discovered, with further chimera
experiments, that p107 ablation with Rb1 ablation eﬃ-
ciently produces retinoblastomas and early mortality in mice
[61]. Similar chimera experiments with homozygous p107
deletion and heterozygous Rb1 deletion were performed to
permit appreciation of the broader tumor spectrum, typical
of humans heterozygous for Rb1 disruption. Eight of the
53 chimeric mice observed developed osteosarcomas, most
of which had lost heterozygosity for Rb1 in the tumor cells
[62]. These data, although overlooked in recent articlesSarcoma 5
arguing from mouse data for the predominance of the p53
pathway as critical and Rb1 as only cooperative, suggest
that a slight variation in pocket protein biology between
mouse and human may have masked the importance of the
retinoblastoma pathway overall in mouse osteosarcomagen-
esis.
The INK4a/ARF locus in the mouse and human has
implications for both the p53 and Rb1 pathways. Although
disruption of at least the INK4a portion is common in
human osteosarcomas that otherwise lack RB silencing [63],
it has received little attention in the mouse. Beginning from
cultured murine mesenchymal progenitors, INK4a/ARF dis-
r u p t i o ni nt a n d e mw i t hc - myc oncogene expression has
proven suﬃcient to generate cells that will form osteosar-
comas when injected orthotopically into syngeneic mice
[64]. In vivo osteosarcomagenesis experiments have yet to be
performed with respect to INK4a/ARF.
4.2. Osteoprogenitor Diﬀerentiation Program Factors. Specu-
lation has reigned over the consideration that Runx2, the
deﬁnitional preosteoblast transcription factor, functions as
a tumor suppressor gene in osteosarcoma. Other Runx
f a m i l yg e n e sh a v eb e e ni m p l i c a t e di nc a n c e r s[ 65]. The
semidiﬀerentiated state of osteoid producing osteosarcoma
cells certainly raises questions about the Runx2-mediated
juncture in osteoblast diﬀerentiation. While Runx2-driven
osteoblast diﬀerentiation is clearly truncated in osteosar-
coma, expression tends to be higher than in osteoblasts
a n dc o r r e l a t e sw i t hap o o rp r o g n o s i s[ 66, 67]. Experiments
in mice and using ex vivo murine cells in culture have
identiﬁed interactions between Runx2 and both p53 and
Rb1 deﬁning the early stages of the osteoblast diﬀerentiation
program [58, 68]. One of the ways that Rb1 loss is felt to
prime for osteosarcomagenesis is by disrupting the feed-
forward cycle between Runx2 and p27kip1 [69]. Disruption
of this feed-forward loop results in osteoprogenitors failing
to terminally diﬀerentiate and exit cell cycle [70]. This
explains the dysfunctional presence of Runx2 in human
osteosarcomas.
Prkar1α was recently proposed as another tumor sup-
pressor gene involved in osteosarcomagenesis in the mouse
[71]. Disruption of this gene reduced the latency to osteosar-
comagenesis in mice transgenic for SV40 large T and small t
antigens expressed by the osteocalcin promoter. Prkar1α is
involved with osteoblast-osteoclast RANK/RANKL interac-
tions and osteoclast diﬀerentiation and activation programs.
A potential challenge to the role of Prkar1α disruption more
generally in osteosarcomagenesis is that the diﬀerentiated
osteoblasts in which this model initiate T-antigen-mediated
genomic distress are also more likely to be embedded within
tight anatomic constraints, perhaps overemphasizing their
need to recruit bone destroying cells to permit geographical
expansion and invasiveness. Prkar1α may be a critical tumor
suppressor for this particular model and perhaps a subset of
osteosarcomas,butnotcriticaloverall.Acorrelationbetween
human osteosarcoma expression of Prkar1α and response
to chemotherapy was also discussed in the same paper but
rendered somewhat equivocal results [71].
4.3. Other General Tumor Suppressors. One recent ﬁnding
is that Wnt-inhibitory factor-1 (Wif1) functions as a tumor
suppressor in osteosarcomas. It was identiﬁed among genes
frequently silenced by promoter hypermethylation in a panel
of human osteosarcoma samples [72]. Mice homozygous
for targeted deletion of Wif1 were noted to have a slight
tendency toward osteosarcomagenesis (2 of 13 mice); when
exposedtobeta-emittingcalcium45radioisotope,thetypical
latencytoosteosarcomagenesiswasshortenedbytwomonths
compared to wild-type controls [72]. Wif1 knockout essen-
tially enhances Wnt signaling, oﬀering the possibility of a
therapeutic target in Wnt signaling itself.
Hypermethylated in cancer 1 (Hic1), by its name, is
another epigenetically modiﬁed locus that has also been
reported to have a tumor suppressor function in osteosar-
coma.Micehomozygousforbothp53andHic1deletionhave
a similar life expectancy overall, compared to p53 deletion
a l o n e ,b u tm u c hm o r ef r e q u e n t l yd e v e l o po s t e o s a r c o m a s
[73]. Hic1 and p53 are located in close proximity on mouse
chromosome 11 and human chromosome 17. Heterozygous
deletion of trans alleles of p53 and Hic1 results in increased
incidenceofmetastaticosteosarcomasovereitherallelealone
[73]. Interestingly, in human tumors, Hic1 is only hyperme-
thylated in tumors with p53 mutations, suggesting that it is a
dependent, necessarily secondary tumor suppressor.
Wwox is a tumor suppressor gene located in one of
the most fragile loci in the mammalian genome. While
heterozygotes canbe induced to generatea variety of tumors,
micehomozygousforGermlinedeletion of Wwox formbone
surface lesions suggestive of chondroblastic osteosarcomas
and then die at a very young age with no additional tumori-
genesis noted [74]. Wwox expression has been assessed in
human tumors as well, where it appeared to have reduced
or absent expression in a majority of osteosarcomas and
increased in response to chemotherapy [75].
Mice bearing deletion of the Xpa gene and heterozy-
gosity for p53 developed more frequent osteosarcomas
than controls when exposed to diethylstilbestrol, but Xpa
knockout alone was not diﬀerent than controls, suggesting
that p53 played a more critical role in these experiments
[76]. Although Xpa disruption has only received minimal
attention in human osteosarcomas, one investigation of
polymorphisms in it and other nucleotide excision repair
genes found shorter event-free survival from osteosarcoma
in cisplatin-treated patients bearing a polymorphism in
ERCC2. Similarly, cooperative disruption of p53 and Brca2
generatedosteosarcomasinmice,buttheincreasedincidence
over baseline was primarily attributed to the former tumor
suppressor [77]. A single case of osteosarcoma in a patient
with a germline Brca2 mutation has been reported, but the
association has not been investigated further [78].
4.4. Surprises. After congenital bilateral retinoblastoma and
Li Fraumeni syndromes (from RB and p53 heterozygous
inactivation in the germline, resp.), the next highest inci-
dence of osteosarcoma in humans occurs in a heritable
syndrome called Rothmund-Thomson syndrome, which
results from homozygosity for RECQL4 helicase ablation. A
model of Recql4 helicase disruption has been generated in6 Sarcoma
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Figure 3: Osteosarcomagenesis has been tested from a range of cells of origin along the diﬀerentiation pathway of osteoblasts. Cre-
recombinase expression driven from the Prx1, osterix,a n dcollagen 1a1 promoters has generated osteosarcomas in mice when used for the
conditional inactivation of p53 with or without Rb1. The osteocalcin promoter, deﬁning a late stage of osteoblast diﬀerentiation usually not
expressed in osteosarcoma cells directly, has proven suﬃcient for osteosarcomagenesis, when used to drive SV40 large and small T antigens.
t h em o u s eb yg e n et a r g e t i n g ,b u to s t e o s a r c o m a sh a v en o t
been identiﬁed, despite recapitulation of other features of
the autosomal recessive heritable disorder [79, 80]. Because
RECQL4helicasehasnotbeenfoundtobemutatedordeleted
insporadichumanosteosarcomas,itisfeltthatitsdisruption
represents more of a route to generate genomic instability
generally than the silencing of a speciﬁc tumor suppressor
important to osteosarcomagenesis.
One of the ﬁrst gene-targeted mouse models noted
to develop frequent osteosarcomas is the merlin or Nf2
knockout [81]. There is no human correlate to this. NF2
deletionhasnotbeendetectedinhumanosteosarcomas[82].
Surprisingly, many attempts at acoustic schwannoma (the
tumor that predictably arises in NF2 heterozygous humans)
formation in these mice have been thwarted by their strong
propensity toward osteosarcomagenesis. The only direct link
that has ﬁt with other knowledge of osteosarcoma so far
is that the Nf2 and p53 genes are in relative proximity in
the genome and the osteosarcomas that form often lose one
or both alleles of p53 a sw e l l .H o w e v e r ,o v e r e x p r e s s i o no f
ezrin is important to human osteosarcomagenesis, especially
development of the metastatic phenotype [48]. Nf2,o r
merlin, is named as the moesin ezrin radixin like protein. A
possiblerelationshipbetweenmerlindisruptioninthemouse
and ezrin overexpression in humans has yet to be deciphered
for osteosarcomagenesis.
5. Tissue of Origin
The anatomic placement of most successfully osteosarco-
magenic chemicals in the metabolically active metaphyses
of long bones and the natural homing of alpha-emitting
heavy metals to the same both make some philosophical
comment on the osteosarcoma tissue of origin. That said, a
wide variety of cell lineages are typically active even within
this constrained anatomy. Osteosarcomas are pathologically
deﬁned as malignant appearing cells producing bone, but
this can be a small minority of the overall tissue volume
of a given tumor. There can be osteoblastic, chondroblastic,
ﬁbroblastic, and telangiectatic tissue types in any single
osteosarcoma. This fact has long raised the question of
what cell within the bone is the cell in which the program
of oncogenesis begins: marrow stromal cells, mesenchymal
progenitor cells, stem cells, diﬀerentiated osteoblasts, or
hematopoietic progenitors.
The tools for conditional gene disruption and onco-
gene activation have greatly enhanced our capacity to test
for speciﬁc cell types of origin (Figure 3). Of course, all
that can really be tested with any of these experiments
is osteosarcomagenic suﬃciency or lack thereof of the
induced derangement in the given cell expressing a speciﬁc
promoter. A variety of promoters have proven suﬃcient to
drive osteosarcomagenesis enacting the speciﬁc conditional
derangements planned. SV40 transgenic promoters included
the alpha-amylase promoter [49, 52], the heat shock protein
70 promoter from Drosophila [50], and the myelin basic
protein promoter [51], each of which managed to generate
osteosarcomas in mice, conﬁrming that each was expressed
in at least some suﬃcient cells of origin.
With Cre-lox conditional ablation of p53 as the given
derangement, diﬀerent mesenchymal and preosteoblast pro-
moters have proven suﬃcient for osteosarcomagenesis. The
ﬁrst tried was a collagen 1α1 promoter fragment, which
also generated a number of lymphomas, suggesting leakiness
into earlier mesenchyme as the possible source of suﬃcient
originating cells [58]. Others have used the Osterix promoter
to drive Cre-mediated conditional ablation of p53 with or
without tandem Rb1 conditional ablation [53, 54]. This
should be expressed in committed but not yet termi-
nally diﬀerentiated osteoprogenitors. These mice formed
some adipocytic tumors in addition to the high incidence
of osteosarcoma, also suggesting some contribution of
either dediﬀerentiation after tumor suppressor silencing or
promoter leakiness into earlier multipotent mesenchyme.
Finally, Prx1-Cre was used to drive tumor suppressor
silencing in lateral plate mesoderm cells and what certainly
remains pluripotent mesenchymal progenitors [83]. These
mice developed a number of soft-tissue sarcomas as well as
osteosarcomas, highlighting the originating cells’ pluripo-
tency.
The genetic mouse model initiating osteosarcomagenesis
in the most diﬀerentiated cells uses the osteocalcin promoter
toexpresslargeandsmallTantigensfromSV40[71].Clearly,
as u ﬃciently strong sledge hammer to the genome can pro-
duce osteosarcomas even from what should be cells that have
exited cell cycle. It may be that a lesser hit in the same cells
wouldproveinsuﬃcienttodriveosteosarcomagenesis.Allwe
know is that we have not pushed against the utter extreme
yet for osteosarcomagenesis from more diﬀerentiated cells.
Further,wearenoclosertoknowingwhichofthesesuﬃcientSarcoma 7
osteoprogenitorsismostfrequentlytheactualcelloforiginin
humans.
6. Host Factors
Although this has received the least attention so far from
investigators in the ﬁeld, mice also have been manipulated
to identify the eﬀects of the background strain or presence
of speciﬁc germline expressions or disruptions on other
methodsofinducingosteosarcomagenesis.Notlongafterthe
report of the ﬁrst targeted disruption of p53 in the mouse, a
paper compared the cancer spectrum and incidence between
the 129/Sv strain and a mixed C57BL/6+129/Sv strain,
ﬁndingnosigniﬁcantdiﬀerenceforosteosarcomaspeciﬁcally
[84]. The rates of plutonium-induced osteosarcomagenesis
were not signiﬁcantly diﬀerent between C3H/He, C57BL/6,
and B6C3F1 strains in another study [85].
Surgical hypophysectomy in mice prior to implantation
of grafted tumors suggested the role of Igf1 in osteosarco-
magenesis [86]. Later host mice engineered genetically to
have Igf1 gene ablation demonstrated similar results [87,
88]. Certainly, these were models intended to ask speciﬁc
questions about pathway contributions rather than identify
the typical etiologies behind human osteosarcoma, but they
highlight an area of research that is already taking oﬀ with
respect to other cancers and host-tumor interactions. With
the technology for deep sequencing of polymorphisms and
their variance between strains of mice, we may eventually be
able to understand much about the more subtle host genetic
contributions to risk of osteosarcoma.
One notable and unusual study of host factors in
osteosarcomagenesis came in the toxicity screening of teri-
paratide or PTH(1-34). Fischer 344 rats developed high
rates of osteosarcoma from prolonged administration of the
parathyroid hormone biological analog, even at lower doses
[89]. No human correlate to this has been encountered,
with only two osteosarcoma cases identiﬁed out of over
430,000 human individuals treated with the drug [90].
Treatment of human and murine cells as well as mice
in vivo with teriparatide-generated DNA double-stranded
breaks and chromosomal abnormalities [91]. While this may
contribute mechanistically to osteosarcomagenesis in the rat,
the mechanism by which PTH(1-34) generates DNA and
chromosomal damage is not yet elucidated. Interestingly,
treatment of Fischer 344 rats with the full-length PTH(1-
84), which includes the C-terminal domain, did not induce
osteosarcomas as eﬃciently at lower doses [92].
7. Conclusions
With the persistent elusiveness of a precursor lesion for
osteosarcoma,eveninverypredictablegeneticmousemodels
of the disease, we continue to learn most of what we know by
candidategeneorcandidateinsultapproaches,testingalways
for suﬃciency in osteosarcomagenesis, but never necessity.
We know that appropriately located chemical carcinogens or
applied radiation rays or alpha-emitting radioisotopes have
all proven suﬃcient to drive osteosarcomagenesis by driving
mutagenesis and chromosomal instability, but genetically
induced aneuploidy alone is not usually suﬃcient. We have
learned that, when appropriately accounting for a mouse-
speciﬁc Rb1 redundancy from p107, disruption of either
the Rb1 pathway or p53 alone in the mouse generally is
suﬃcient to drive osteosarcomagenesis. Their combination
is alarmingly eﬃcient, consistent with the observation
from human osteosarcomas that both pathways are usually
disrupted by some means in tumors. We have learned that
these disruptions can initiate osteosarcomagenesis in undif-
ferentiated mesenchymal progenitors or even committed cell
types.
Other pathways, oncogenes, and tumor suppressors
have been identiﬁed, some of which are clearly dependent
on other disruptions or the application of other genetic
insults to drive osteosarcomagenesis. No doubt, improved
oncogenomic techniques will inspire yet new mouse models
and the testing of the suﬃciency of newly identiﬁed tumor
suppressor disruptions and oncogene activations in the
mouse. The new ﬁelds of host and niche biology as the
environments in which cancers initiate and develop can also
be expected to bring new knowledge to osteosarcomagenesis
as well as further innovative experimentation in the mouse.
There remain challenges to the use of the mouse as
a model organism for human osteosarcomagenesis. First,
rodents more readily form osteosarcomas than do humans.
Second, there are a number of speciﬁc pathways that are
diﬃcult to translate between the two. Other challenges, such
as the lack of true lamellar bone in the mouse, highlight
critical discrepancies in healthy bone biology between the
species. Many scientists argue that genetically engineered or
transplanted syngeneic osteosarcomas in rats, which have
lamellar bone structure, or spontaneous osteosarcomas in
canines may provide better preclinical models for drug
testing and so forth. Nonetheless, the mouse as preclinical
model may be less enlightening than the mouse as testing
platform for the induction of osteosarcomas. The breadth
and depth of genomic understanding of the mouse and
facility with which it can be experimentally manipulated
will not soon be replicated in any other mammalian species.
Whilecaremustbetakenininterpretingresultsinthemouse,
attending to interspecies variations, that same attention
can broaden our understanding of this complex disease
even further. For example, speciﬁc biological eccentricities
such as the pocket protein redundancy in mice have not
prevented illumination of the human disease; they just
require more careful attention to all the available literature.
In similar fashion, perhaps further interrogation of Nf2
in murine osteosarcomagenesis may yet highlight pathways
that are important, but unrecognized in the human dis-
easem.
Although mice and humans are decidedly diﬀerent in
many ways, most of the knowledge gained from mouse
modeling has been validated in human clinical samples
and cell lines. Clearly, the opportunity to prospectively
test hypotheses in mouse-modeled osteosarcomagenesis is
unique. There is doubtless much that remains to be learned
from the mouse with regard to osteosarcoma initiation,
progression, and metastasis.8 Sarcoma
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